Regenxbio Inc (RGNX)
9.61
+0.43
(+4.68%)
USD |
NASDAQ |
Nov 22, 14:05
Regenxbio Total Liabilities (Quarterly): 217.70M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 217.70M |
| June 30, 2024 | 221.11M |
| March 31, 2024 | 238.55M |
| December 31, 2023 | 262.23M |
| September 30, 2023 | 270.69M |
| June 30, 2023 | 276.60M |
| March 31, 2023 | 282.69M |
| December 31, 2022 | 317.07M |
| September 30, 2022 | 319.97M |
| June 30, 2022 | 322.92M |
| March 31, 2022 | 335.70M |
| December 31, 2021 | 349.61M |
| September 30, 2021 | 338.98M |
| June 30, 2021 | 329.16M |
| March 31, 2021 | 324.94M |
| December 31, 2020 | 330.41M |
| September 30, 2020 | 125.51M |
| June 30, 2020 | 51.88M |
| March 31, 2020 | 43.78M |
| December 31, 2019 | 47.71M |
| Date | Value |
|---|---|
| September 30, 2019 | 40.84M |
| June 30, 2019 | 34.55M |
| March 31, 2019 | 31.98M |
| December 31, 2018 | 34.97M |
| September 30, 2018 | 20.93M |
| June 30, 2018 | 18.76M |
| March 31, 2018 | 17.88M |
| December 31, 2017 | 15.65M |
| September 30, 2017 | 14.60M |
| June 30, 2017 | 12.68M |
| March 31, 2017 | 11.23M |
| December 31, 2016 | 11.00M |
| September 30, 2016 | 15.75M |
| June 30, 2016 | 9.897M |
| March 31, 2016 | 6.383M |
| December 31, 2015 | 4.572M |
| September 30, 2015 | 5.506M |
| June 30, 2015 | 6.172M |
| December 31, 2014 | 9.189M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
43.78M
Minimum
Mar 2020
349.61M
Maximum
Dec 2021
250.36M
Average
279.65M
Median
Total Liabilities (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 111.07M |
| EyePoint Pharmaceuticals Inc | 82.18M |
| Cassava Sciences Inc | 57.11M |
| Vertex Pharmaceuticals Inc | 6.609B |
| Sarepta Therapeutics Inc | 2.379B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 519.11M |
| Shareholders Equity (Quarterly) | 301.42M |
| Current Ratio | 3.051 |